Langdon Miller - Cleveland BioLabs President and Chief Medical Officer
President
Dr. Langdon L. Miller, MD. is President of the Company. He previously served as a strategic adviser to the Company beginning in 2014. Dr. Miller has maintained a drug development consultancy, Sound Clinical Solutions, SP, located in Seattle, WA since 2013 and has served as a consulting Chief Medical Officer to Oncternal Therapeutics, Inc, located in San Diego, CA, since August 2016. Dr. Miller has more than 25 years of experience in the design and conduct of translational and clinical drug development programs in oncology and orphan diseases . He has worked in all phases of drug development, from firstinhuman studies through pivotal registrationdirected trials to medical affairs programs and has filed multiple INDs, CTAs, NDAs and orphan drug applications. Dr. Miller played major roles in the development of filgrastim and sargramostim, in the regulatory approvals of irinotecan, exemestane, epirubicin, dexrazoxane, sunitinib, and idelalisib in several cancers, and in validating new endpoints for Duchenne muscular dystrophy and cystic fibrosis. He has extensive experience in the generation, analysis, presentation, and justification of drug development programs before regulatory authorities, advisory committees, investigators, investors, and business development partners. He has authored over 100 regulatory documents and publications. Dr. Miller has held leadership positions in government and in large and small biopharmaceutical companies. He was a Senior Investigator at the National Cancer Institute from 1989 to 1995 before transitioning to industry at the Pharmacia Corporationrationration. since 2015.
| Age | 64 |
| Tenure | 9 years |
| Phone | 716 849-6810 |
| Web | www.cbiolabs.com |
Cleveland BioLabs Management Efficiency
The company has return on total asset (ROA) of (20.33) % which means that it has lost $20.33 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.86) %, meaning that it created substantial loss on money invested by shareholders. Cleveland BioLabs' management efficiency ratios could be used to measure how well Cleveland BioLabs manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Richard Kinzley | Black Hills | 58 | |
| Benjamin Bolanos | One Liberty Properties | 27 | |
| Brian Iverson | Black Hills | 61 | |
| Richard Figueroa | One Liberty Properties | 56 | |
| Israel Rosenzweig | One Liberty Properties | 77 | |
| Kimberly Nooney | Black Hills | 52 | |
| Mark Lundy | One Liberty Properties | 57 | |
| Sean DellOrto | Park Hotels Resorts | 49 | |
| Brian Larson | Boyd Gaming | 62 | |
| Steve Hightower | Presidio Property Trust | 56 | |
| Jeffrey Gould | One Liberty Properties | 58 | |
| Ted Bogich | Boyd Gaming | N/A | |
| Josh Hirsberg | Boyd Gaming | 62 | |
| Scott Buchholz | Black Hills | 58 | |
| Theodore Bogich | Boyd Gaming | 68 | |
| Esther Newbrough | Black Hills | N/A | |
| Steve Thompson | Boyd Gaming | 55 | |
| Jennifer Landis | Black Hills | 49 | |
| David Kalish | One Liberty Properties | 77 | |
| Anthony CPA | Ark Restaurants Corp | 60 | |
| Erik Keller | Black Hills | 60 | |
Management Performance
| Return On Equity | -31.86 | |||
| Return On Asset | -20.33 |
Cleveland BioLabs Leadership Team
Elected by the shareholders, the Cleveland BioLabs' board of directors comprises two types of representatives: Cleveland BioLabs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cleveland. The board's role is to monitor Cleveland BioLabs' management team and ensure that shareholders' interests are well served. Cleveland BioLabs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cleveland BioLabs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Evdokimova, Director | ||
| Richard McGowan, Independent Director | ||
| Rachel Levine, VP of Investor Relations | ||
| Anthony Principi, Independent Director | ||
| Ivan Persiyanov, Director | ||
| Yulia Lebedina, Director | ||
| Natalia Khudyk, Director | ||
| James Antal, Independent Director | ||
| Langdon Miller, President and Chief Medical Officer | ||
| Tatiana Levina, Director | ||
| Randy Saluck, Independent Director | ||
| John Szydlo, | ||
| Andrei Gudkov, Chief Scientific Officer, Director | ||
| Alexey Nechaev, Independent Director | ||
| Natalia Saraeva, Director | ||
| Ivan Fedyunin, Director | ||
| Yakov Kogan, CEO, Director | ||
| Alexander Andryushechkin, Director | ||
| Lea Verny, Independent Director | ||
| Konstantin Gorshkov, Director | ||
| Neil Lyons, CFO | ||
| Daniil Talyanskiy, Director |
Cleveland Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cleveland BioLabs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.86 | |||
| Return On Asset | -20.33 | |||
| Current Valuation | 66.46 M | |||
| Shares Outstanding | 15.47 M | |||
| Shares Owned By Insiders | 50.26 % | |||
| Shares Owned By Institutions | 6.67 % | |||
| Number Of Shares Shorted | 30.07 K | |||
| Price To Earning | (4.57) X | |||
| Price To Book | 5.32 X | |||
| Price To Sales | 458.71 X |
Pair Trading with Cleveland BioLabs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cleveland BioLabs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cleveland BioLabs will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Cleveland Stock
If you are still planning to invest in Cleveland BioLabs check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cleveland BioLabs' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |